This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTE-162 administered once daily for 2 weeks in subjects with cryopyrin-associated periodic syndrome (CAPS)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change and percent change from baseline to end of treatment (EOT) in high-sensitivity C-reactive protein (hs-CRP)
Timeframe: 2 Weeks
Change and percent change from baseline to EOT in Serum amyloid A (SAA)
Timeframe: 2 Weeks
Change and percent change from baseline to EOT in Interleukin (IL)-6
Timeframe: 2 Weeks
Change and percent change from baseline to EOT in Key symptom score (KSS)
Timeframe: 2 Weeks
Change and percent change from baseline to EOT in Individual symptom score on Daily Health Assessment Form, Second Generation (DHAF2)
Timeframe: 2 Weeks
Change and percent change from baseline to EOT in Global assessments of disease activity on DHAF2
Timeframe: 2 Weeks
Change and percent change from baseline to EOT in Global CAPS symptom assessment by the Investigator
Timeframe: 2 Weeks
Change and percent change from baseline to EOT in Individual CAPS symptom assessment by the Investigator
Timeframe: 2 Weeks
Number of adverse events
Timeframe: 4 Weeks
JTE-162 post-dose plasma concentrations on Day 1
Timeframe: 1 Day
JTE-162 trough plasma concentrations on Days 2, 3 and 4, and at the Week 2 Visit (Day 15±2)
Timeframe: Day 2, Day 3, Day 4 and Day 15±2